Despite vaccination against SARS-CoV-2, the COVID-19 pandemic continues to expand worldwide. Early reports suggested that only a minor proportion of pediatric population is affected by COVID-19 in comparison to adult population. Three percent of pediatric population needed admission to intensive care units, and only a small number of deaths have been reported. Available literature suggests that infants (children under 1 year) seem to be more vulnerable to COVID-19 virus infection with a higher severity of illness compared with other pediatric ages. Requirement for neonatal mechanical ventilation is 20%–22.4% (vs. 4% in children) (1).
Alamdari,D Hamidi and Bhushan,B . (2022). Methylene Blue for the Treatment of COVID-19 in Pediatrics. Journal of Pediatric Perspectives, 10(1), 15281-15284. doi: 10.22038/ijp.2021.59339.4625
MLA
Alamdari,D Hamidi, and Bhushan,B . "Methylene Blue for the Treatment of COVID-19 in Pediatrics", Journal of Pediatric Perspectives, 10, 1, 2022, 15281-15284. doi: 10.22038/ijp.2021.59339.4625
HARVARD
Alamdari D Hamidi, Bhushan B. (2022). 'Methylene Blue for the Treatment of COVID-19 in Pediatrics', Journal of Pediatric Perspectives, 10(1), pp. 15281-15284. doi: 10.22038/ijp.2021.59339.4625
CHICAGO
D Hamidi Alamdari and B Bhushan, "Methylene Blue for the Treatment of COVID-19 in Pediatrics," Journal of Pediatric Perspectives, 10 1 (2022): 15281-15284, doi: 10.22038/ijp.2021.59339.4625
VANCOUVER
Alamdari D Hamidi, Bhushan B. Methylene Blue for the Treatment of COVID-19 in Pediatrics. JPP; J Ped Perspect. 2022;10(1):15281-15284. doi: 10.22038/ijp.2021.59339.4625
